Based upon our results, we can suggest that prepared transferrin-conjugated solid lipid nanoparticles (SLNs) has significant potential to deliver the Tamoxifen citrate in the treatment of breast cancer with improved therapeutic activities. This evidence concerns the gene TF and breast carcinoma.